Request Demo
Last update 23 Jul 2026
CAN-1012
Last update 23 Jul 2026
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms 3-((4-((4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)oxy)butyl)(3- (dimethylamino)propyl)amino)-4-(heptadecylamino)cyclobut-3-ene-1,2-dione, CAN 1012, CAN-1012 + [1] |
Target |
Action agonists |
Mechanism TLR7 agonists(Toll like receptor 7 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Login to view timeline
Related
6
Clinical Trials associated with CAN-1012NCT07408856
A Phase I/Ib Study Evaluating Intralesional TLR7 Agonist, CAN1012, in Pre-malignant Ductal Carcinoma in Situ and Lobular Carcinoma in Situ
NCT07620496
A Phase I/Ib Study Evaluating Intralesional TLR7 Agonist, CAN1012, in Pre-malignant Oral Dysplasia
NCT06410703
A Phase Ib/IIa, Dose Escalation, Open-Label Study of Intratumoral CAN1012 Combined With PD-1 in Patients With Unresectable or Metastatic Advanced Solid Tumors
100 Clinical Results associated with CAN-1012
Login to view more data
100 Translational Medicine associated with CAN-1012
Login to view more data
100 Patents (Medical) associated with CAN-1012
Login to view more data
100 Deals associated with CAN-1012
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Locally Advanced Malignant Solid Neoplasm | Phase 2 | China | 27 Jun 2024 | |
| Breast Cancer | Phase 2 | China | - | |
| Liposarcoma | Phase 2 | China | - | |
| Melanoma | Phase 2 | China | - | |
| Ductal Carcinoma | Phase 1 | United States | 01 Aug 2026 | |
| Noninfiltrating Intraductal Carcinoma | Phase 1 | United States | 01 Aug 2026 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | China | 09 Sep 2022 | |
| Colorectal Cancer | Phase 1 | China | 09 Sep 2022 | |
| Colorectal Cancer | Phase 1 | China | 09 Sep 2022 | |
| Merkel Cell Carcinoma | Phase 1 | China | 09 Sep 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 47 | kbcwadditx(zzcrzdjkwi) = tqimcqyefl beleiqroia (egfkzqttdc ) View more | Positive | 17 Oct 2025 | |||
Phase 1 | 21 | porttxxrcg(faazjpnbyv) = nmclaxsydz vrotqlagib (qqfjedbnmz ) View more | Positive | 05 Nov 2024 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free